p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure

Isik, R; Metintas, MUZAFFER; Gibbs, AR; Metintas, SELMA; Jasani, B; Oner, U; Harmanci, E; Demircan, S; Isiksoy, S

doi:10.1053/rmed.2001.1108

p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure

Atıf İçin Kopyala

Isik R., Metintas M., Gibbs A., Metintas S., Jasani B., Oner U., ...Daha Fazla

RESPIRATORY MEDICINE, cilt.95, sa.7, ss.588-593, 2001 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 95 Sayı: 7
Basım Tarihi: 2001
Doi Numarası: 10.1053/rmed.2001.1108
Dergi Adı: RESPIRATORY MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.588-593
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein.